Answers are grounded in this paper and cite their sources.
The discovery of noncoding RNAs (ncRNAs) revolutionised our understanding of gene regulation, marking a paradigm shift in cancer biology. Initially considered transcriptional noise, ncRNAs, including microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), have emerged as critical regulators of gene expression, tumour progression, and therapy resistance. Their role in modulating invasion, metastasis, and tumour heterogeneity highlights their significance in cancer pathophysiology. Advances in transcriptomics have unveiled the potential of ncRNAs as biomarkers and therapeutic targets, exemplified by miRNA-based therapies and lncRNA-targeted interventions. However, challenges remain, particularly in clinical translation, where delivery mechanisms and off-target effects must be addressed. Emerging technologies such as single-cell RNA sequencing and bioinformatics-driven analyses promise to describe ncRNA functions further, improving the precision oncology framework. This editorial highlights the journey of ncRNAs from discovery to their integration into cancer research, emphasising their transformative potential in diagnostics and therapeutics.
No takes yet. Share an insight, caveat, or question.
Ioana Berindan‐Neagoe (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: